Summit Therapeutics (LSE:SUMM) Total Liabilities : £104.33 Mil (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Summit Therapeutics Total Liabilities?

Summit Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was £104.33 Mil.

Summit Therapeutics's quarterly Total Liabilities increased from Sep. 2023 (£96.23 Mil) to Dec. 2023 (£98.95 Mil) and increased from Dec. 2023 (£98.95 Mil) to Mar. 2024 (£104.33 Mil).

Summit Therapeutics's annual Total Liabilities increased from Dec. 2021 (£22.63 Mil) to Dec. 2022 (£441.30 Mil) but then declined from Dec. 2022 (£441.30 Mil) to Dec. 2023 (£98.95 Mil).

Summit Therapeutics Total Liabilities Historical Data

The historical data trend for Summit Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Total Liabilities Chart

Summit Therapeutics Annual Data

Trend

Jan14

Jan15

Jan16

Jan17

Jan18

Jan19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

18.40

17.15

22.63

441.30

98.95

Summit Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															100.05	93.28	96.23	98.95	104.33

Summit Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Summit Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16.12	+	(81.599	+	1.234
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	98.95

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	160.33	-	61.377
	=	98.95

Summit Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	18.446	+	(83.283	+	2.604
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	104.33

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	139.127	-	34.793
	=	104.33

Summit Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Summit Therapeutics (LSE:SUMM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics PLC (LSE:SUMM) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SMMT:USA

Address

2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025

Website

https://www.smmttx.com

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics (LSE:SUMM) Headlines

No Headlines